New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2013
11:28 EDTNDAQ, MTG, AT, EXAS, EQRHigh option volume stocks: NDAQ MTG AT EXAS EQR
News For NDAQ;MTG;AT;EXAS;EQR From The Last 14 Days
Check below for free stories on NDAQ;MTG;AT;EXAS;EQR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2014
11:47 EDTEXASOptions with increasing implied volatilit
Subscribe for More Information
August 18, 2014
10:01 EDTEQROn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Achillion (ACHN) upgraded to Buy from Hold at Deutsche Bank... CNOOC (CEO) upgraded to Neutral from Underperform at Credit Suisse... Dollar General (DG) upgraded to Buy from Neutral at Sterne Agee... Equity Residential (EQR) upgraded to Hold from Underperform at Jefferies... HMS Holdings (HMSY) upgraded to Overweight from Equal Weight at First Analysis... HP (HPQ) upgraded to Buy from Neutral at Monness Crespi... Halcon Resources (HK) upgraded to Buy from Hold at MLV & Co.... KapStone (KS) upgraded to Buy from Hold at Deutsche Bank... Sportsman's Warehouse (SPWH) upgraded at RW Baird... Westlake Chemical (WLK) upgraded to Neutral from Reduce at SunTrust... WisdomTree (WETF) upgraded to Neutral from Sell at Citigroup... Zimmer (ZMH) upgraded to Outperform from Market Perform at William Blair.
08:05 EDTEXASExact Sciences risk/reward positive, says Canaccord
Canaccord said the scenario analysis of upcoming catalysts suggests positive risk/reward for the shares of Exact Sciences. The firm cited its potential for reimbursement approvals form both the CMS and commercial payers. Shares of Exact Sciences remain Buy rated with a $21 price target.
05:29 EDTEQREquity Residential upgraded to Hold from Underperform at Jefferies
Jefferies upgraded Equity Residential to Hold with a $62 price target.
August 14, 2014
06:18 EDTNDAQNASDAQ, CME Group eyes Barclays index division, Bloomberg says
Subscribe for More Information
August 13, 2014
08:50 EDTEXASExact Sciences CMS approval expected by early September, says Canaccord
Canaccord met with Exact Sciences management and came away confident in the CMS' preliminary reimbursement amount, which the firm expects by early September. Canaccord also noted checks into the company's call center indicated strong interest in Cologuard and it expects targeted digital advertising to raise awareness of its product. The firm raised its price target on the stock to $21 from $20 and keeps its Buy rating on the shares.
August 12, 2014
09:35 EDTEXASActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GOOG C TSL EXAS BAC DNDN JNJ TSLA
09:21 EDTEXASOn The Fly: Pre-market Movers
Subscribe for More Information
07:24 EDTEXASExact Sciences FDA approval priced into shares, says Maxim
Subscribe for More Information
07:14 EDTEXASExact Sciences announces FDA approved Cologuard
Subscribe for More Information
August 11, 2014
16:24 EDTEXASFDA announces approval of Exact Sciences colorectal screening test
The FDA said it approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or precursors to cancer. The FDA added that the Centers for Medicare & Medicaid Services proposes to cover the Cologuard test once every three years for Medicare beneficiaries who meet certain criteria. Cologuard is manufactured by Exact Sciences. Reference Link
15:27 EDTMTGSusquehanna to hold a forum
Subscribe for More Information
06:57 EDTMTGUBS to hold a conference
Subscribe for More Information
August 8, 2014
07:01 EDTMTGMGIC Investment reports July primary new insurance written $3.6B
MGIC Investment reports primary new insurance written for May of $3.6B and beginning primary delinquent inventory of 85,416 loans.
August 7, 2014
17:39 EDTATAtlantic Power sees FY14 project adjusted EBITDA $280M-$305M
Sees FY14 Project adjusted EBITDA for APLP alone of $165M-$175M and free cash flow of $0-$25M, which excludes approximately $49M of debt refinancing transaction costs and $8M of Piedmont debt payment.
17:37 EDTATAtlantic Power reports Q2 EPS (49c), may not compare with consensus (20c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use